Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-12-30
2010-12-07
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C530S324000, C530S326000
Reexamination Certificate
active
07846900
ABSTRACT:
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
REFERENCES:
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 5545614 (1996-08-01), Stamler et al.
patent: 5602143 (1997-02-01), Krauss
patent: 5625056 (1997-04-01), Genieser et al.
patent: 5665861 (1997-09-01), Forssmann et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 2002/0094326 (2002-07-01), Donahue et al.
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2004/0229784 (2004-11-01), Vesely
patent: 2005/0176641 (2005-08-01), Bakis et al.
patent: 2005/0209139 (2005-09-01), Vesely
patent: 2005/0272650 (2005-12-01), Mohapatra
patent: 2006/0014689 (2006-01-01), Vesely
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2006/0276382 (2006-12-01), Mohapatra
patent: 2007/0265204 (2007-11-01), Mohapatra et al.
patent: 2008/0039394 (2008-02-01), Vesely
patent: 2008/0070858 (2008-03-01), Mohapatra
patent: 2008/0214437 (2008-09-01), Mohapatra et al.
patent: 2009/0062206 (2009-03-01), Vesely
patent: 2009/0176706 (2009-07-01), Mohapatra
patent: WO 2004/022003 (2004-03-01), None
patent: WO 2004/083236 (2004-09-01), None
patent: WO 2005/094420 (2005-10-01), None
patent: WO 2006/026536 (2006-03-01), None
patent: WO 2007/127487 (2007-11-01), None
patent: WO 2007/130672 (2007-11-01), None
patent: WO 2009/073527 (2009-06-01), None
ATCC No. CCL-248 (T84, 1984).
Benjamin, B.A. et al. “Effect of proANF-(31-67) on sodium excretion in conscious monkeys”Am J Physiol Regul Integr Comp Physiol, 1995, pp. R1351-R1355, vol. 269, abstract.
Buskens, C. et al. “Adenocarcinomas of the Gastro-Esophageal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression”Digestive Disease Week Abstracts and Itinerary Planner, 2003, Abstract No. 850.
Capizzi, R.L. “Molecular and Cellular Biology of Cancer” In: Internal Medicine, 4th Edition, Ed. Jay Stein, Elsevier Science, 1994, pp. 707-729.
Carter, S.K. et al. “Chemotheraphy of Cancer” Second Edition, John Wiley & Sons: New York, 1981, Appendix C.
Chow, W.H. et al. “Rising Incidence of Renal Cell Cancer in the United States”JAMA, May 1999, pp. 1628-1631, vol. 281, No. 17.
Clark, J.I. et al. “Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial”Journal of Clinical Oncology, Aug. 15, 2003, pp. 3133-3140, vol. 21, No. 16.
Cohen, H.T. et al. “Medical Progress: Renal-Cell Carcinoma”The New England Journal of Medicine, Dec. 8, 2005, pp. 2477-2490, vol. 353, No. 23.
Daggubati, S. et al. “Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators”Cardiovascular Research, 1997, pp. 246-255, vol. 36.
De Palo, E.F. et al. “Circulating Immunoreactive proANP(1-30) and proANP(31-67) in Sedentary Subjects and Athletes”Clinical Chemistry, 2000, pp. 843-847, vol. 46, No. 6.
Dermer, G.B. “The Last Word: Another Anniversary for the War on Cancer”Bio/Technology, Mar. 1994, p. 320, vol. 12.
Dietz, J.R. et al. “Evidence supporting a physiological role for proANP-(1-30) in the regulation of renal excretion”Am J Physiol Regul Integr Comp Physiol, 2001, pp. R1510-R1517, vol. 280.
Fisher, E. et al. “Comparative Histopathologic, Histochemical, Electron Microscopic and Tissue Culture Studies of Bronchial Carcinoids and Oat Cell Carcinomas of Lung”Am J Clin Pathol, 1978, pp. 165-172, vol. 69.
Franz, M. et al. “N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment”Kidney International, 2000, pp. 374-383, vol. 58.
Franz, M. et al. “Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases”Kidney International, 2001, pp. 1928-1934, vol. 59.
Freshney, R.I. “Culture of Animal Cells: A Manual of Basic Technique” Alan R. Liss, Inc.: New York, 1983, pp. 3-4.
Friedman, H.S. et al. “Glioblastoma Multiforme and the Epidermal Growth Factor Receptor”N Engl J Med, Nov. 2005, pp. 1997-1999, vol. 353, No. 19.
Garrett, M.D. et al. “Discovering Novel Chemotherapeutic Drugs for the Third Millennium”European Journal of Cancer, 1999, pp. 2010-2030, vol. 35, No. 14.
Gower, W.R. et al. “Four Peptides Decrease Human Colon Adenocarcinoma Cell Number and DNA Synthesis via Cyclic GMP”International Journal of Gastrointestinal Cancer, 2005, pp. 77-88, vol. 36, No. 2.
Gratzner, H.G., “Monoclonal Antibody to 5-Bromo- and 5-Iododeoxyuridine: A New Reagent for Detection of DNA Replication”Science, Oct. 29, 1982, pp. 474-475, vol. 218.
Gunning, M.E. et al. “Atrial Natriuretic Peptide(31-67)Inhibits Na+Transport in Rabbit Inner Medullary Collecting Duct Cells: Role of Prostaglandin E2”Journal of Clinical Investigation, May 1992, pp. 1411-1417, vol. 89.
Gura, T. “Cancer Models: Systems for Identifying New Drugs are Often Faulty”Science, Nov. 7, 1997, pp. 1041-1042, vol. 278.
Heim, J.M. et al. “Urodilatin and β-ANF: Binding Properties and Activation of Particulate Guanylate Cyclase”Biochemical and Biophysical Research Communications, Aug. 30, 1989, pp. 37-41, vol. 163, No. 1.
Hunter, E.F.M. et al. “Analysis of peptides derived from Pro Atrial Natriuretic Peptide that circulate in man and increase in heart disease”Scandinavian Journal of Clinical and Laboratory Investigation, 1998, pp. 205-216, vol. 58.
Jemal, A. et al. “Cancer Statistics, 2005”CA: A Cancer Journal for Clinicians, 2005, pp. 10-30, vol. 55.
Kaiser, J. et al. “Cancer: First Pass at Cancer Genome Reveals Complex Landscape”Science, Sep. 8, 2006, p. 1370, vol. 313.
Krontiris, T.G. “Molecular and Cellular Biology of Cancer” In: Internal Medicine, 4th Edition, Ed. Jay Stein, Elsevier Science, 1994, pp. 699-707.
Kumar, R. et al. “Stimulation of atrial natriuretic peptide receptor/guanylyl cyclase- A signaling pathway antagonizes the activation of protein kinase C-α in murine Leydig cells”Biochimica et Biophysica Acta, 1997, pp. 221-228, vol. 1356.
La Vecchia, C. et al. “Smoking and Renal Cell Carcinoma”Cancer Research, Sep. 1, 1990, pp. 5231-5233, vol. 50.
Linder, M.W. et al. “Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency”Clinical Chemistry, 1997, pp. 254-266, vol. 43, No. 2.
Martin, D.R. et al. “Three peptides from the ANF prohormone NH2are natriuretic and/or kaliuretic”Am J Physio Renal Physiol, Dec. 1990, pp. F1401-F1408, vol. 258, abstract.
McLaughlin, J.K. et al. “A Population-Based Case-Control Study of Renal Cell Carcinoma”,J Natl Cancer lnst, Feb. 1984, pp. 275-284, vol. 72.
Mellinghoff, I.K. et al. “Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors”The New England Journal of Medicine, Nov. 2005, pp. 2012-2024, vol. 353, No. 19.
Morstyn, G. et al. “Immunohistochemical Identification of Proliferating Cells in Organ Culture Using Bromodeoxyuridine
Monshipouri Maryam
Saliwanchik Lloyd & Saliwanchik
Tsay Marsha M
University of South Florida
LandOfFree
Cancer treatment using C-type natriuretic peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment using C-type natriuretic peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment using C-type natriuretic peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170674